Trade setup intelligence
Charts, patterns, liquidity, and profile weighting stay together before a setup is surfaced.
Signal through the silt.
Stocks, crypto and news catalysts, ranked into decisions
Follow market prices, charts and current catalysts without an account. When you need a decision workflow, move into ranked intelligence with data-quality checks and risk-aware review.
- Public markets
- Stocks · Crypto · NFTs
- Catalysts
- Source attributed
- Member intelligence
- Risk gated
Automated Market Intelligence
News Catalysts Mixed Directly with Stock Signals
News aggregation engine
Market-moving headlines are normalized, scored, and matched to the stocks they can move.
Automated controls
Automation is gated by data quality, risk limits, and explicit confidence thresholds.
Signal Workflow
Built Around the Decision Path
Ingest
Market headlines and bars enter one data-quality boundary.
Score
Catalysts are separated into bullish, neutral, and bearish context.
Rank
Opportunity boards blend catalyst impact with chart and risk signals.
Control
Execution-facing actions stay behind operator and risk checks.
Current Catalysts
Latest Market Headlines
Source-attributed headlines captured in the last hours, each linked to the public stock and crypto pages it mentions. Browse all market news
Summa Defence Announces Changes to Executive Management Team
Summa Defence Oyj has reported a change within its executive management team.
Tecnotree Corporation Extraordinary General Meeting Approves Dividend Distribution
Tecnotree Corporation's Extraordinary General Meeting has officially approved the Board of Directors' proposal for a dividend distribution.
Lamor Considers Directed Share Issue and Negotiates Financing Covenants
Lamor Corporation Oyj has announced it is exploring a potential directed share issue to strengthen its liquidity and is currently in negotiations with lenders regarding adjustments to its financial covenants.
Lindex Group Reports Q3 2026 Financial Results
Lindex Group announced its third-quarter 2026 financial results, highlighting a 7% increase in revenue and an adjusted operating margin of 10%.
Canaccord Genuity Reaffirms Buy Rating on Compass Therapeutics
Canaccord Genuity has reaffirmed its Buy rating on Compass Therapeutics following the publication of positive Phase 2/3 clinical trial results.
Canaccord Genuity Upgrades Eldorado Gold to Buy
Canaccord Genuity has upgraded its rating for Eldorado Gold Corporation to Buy from Hold, setting a price target of CA$57.
Real signals or no signal
The system only ranks opportunities when real market and catalyst data is available. Missing data produces a clear unavailable state instead of noise.
Review integrations